Wednesday, October 23, 2013
BioDatomicshas introduced the company’s first commercial product, BioDT, an open source suite of next generation sequencing (NGS) data analysis software and services. The new platform offers performance and an intuitive interface, enabling genomic and biomedical researchers to more quickly glean meaningful insights from their data.
Sideris Pharmaceuticals has entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive right to acquire Sideris and its lead asset, the iron-chelating candidate SP-420. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $300 million.
An article to be published in the American Journal of Public Health recommends changing the federal regulations that govern research oversight to address continued underrepresentation of minorities in research studies.
MRC Technology, a technology transfer organization, is collaborating with Boston University to develop an anti-IL-16 antibody for use in treatment of inflammatory diseases and Ischaemic Reperfusion Injury (IRI). The project is funded in part through a Biomedical Catalyst award of $932,000 granted to MRC Technology in 2012.